🧪
hypothesis

NAC + Ferrostatin-1 Combination for Peroxynitrite-Ferroptosis Crosstalk

Hypothesis

NAC + Ferrostatin-1 Combination for Peroxynitrite-Ferroptosis Crosstalk

Combining NAC (GSH precursor/peroxynitrite scavenger) with ferrostatin-1 (specific ferroptosis inhibitor) provides dual blockade against convergent injury pathways post-cardiac arrest.
🧬 Convergent: GSH depletion + peroxynitrite + lipid radical accumulation🩺 neurodegeneration🎯 Composite 53%💱 $0.53▼1.1%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 3 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.72 (15%) Evidence 0.62 (15%) Novelty 0.68 (12%) Feasibility 0.35 (12%) Impact 0.60 (12%) Druggability 0.32 (10%) Safety 0.58 (8%) Competition 0.55 (6%) Data Avail. 0.60 (5%) Reproducible 0.65 (5%) KG Connect 0.50 (8%) 0.530 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite53%

🧪 Overview

Combining NAC (GSH precursor/peroxynitrite scavenger) with ferrostatin-1 (specific ferroptosis inhibitor) provides dual blockade against convergent injury pathways post-cardiac arrest. While mechanistically interesting, Ferrostatin-1 is not a clinical candidate (unknown PK, toxicity, BBB penetration). Attribution problem is compounded: if the combination works, which component mediates which effect? The peroxynitrite-GPX4 crosstalk is plausible but incompletely validated as primary mechanism in post-CA injury.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["GSH Depletion<br/>Glutathione Synthesis Impairment"]
    B["GPX4 Inactivation<br/>Phospholipid Peroxidase Loss"]
    C["Lipid Peroxidation<br/>Polyunsaturated Fatty Acid Radical Chain"]
    D["Peroxynitrite Formation<br/>Nitric Oxide plus Superoxide Convergence"]
    E["Ferroptotic Cell Death<br/>Iron-Dependent Membrane Rupture"]
    F["NAC Supplementation<br/>GSH Precursor and Peroxynitrite Scavenger"]
    G["Ferrostatin-1<br/>Lipid Radical Termination and Ferroptosis Block"]
    A --> B
    B --> C
    D --> C
    C --> E
    F -.->|"restores"| A
    G -.->|"inhibits"| C
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1b5e20,stroke:#81c784,color:#81c784
    style G fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix3 supports3 contradicts
Supports
Peroxynitrite inactivates GPX4
PMID:32084338
Supports
NAC protects against ferroptosis via multiple mechanisms
PMID:31700137
Supports
Ferroptosis-peroxynitrite interplay established in tissue injury
PMID:34145432
Contradicts
Ferrostatin-1 is not a clinical candidate; no IND-enabling studies
PMID:N/A
Contradicts
Combinatorial therapy increases regulatory burden without synergy demonstration
PMID:N/A
Contradicts
Fer-1 pharmacokinetics and toxicity uncharacterized for clinical use
PMID:N/A
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — CONVERGENT:

No curated PDB or AlphaFold mapping for CONVERGENT: yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for Convergent: GSH depletion + peroxynitrite + lipid radical accumulation →

No DepMap CRISPR Chronos data found for Convergent: GSH depletion + peroxynitrite + lipid radical accumulation.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0114
Events (7d)
1
Price History
▼1.1%

💾 Resource Usage

LLM Tokens
12,340
$0.0370
Total Cost
$0.0370

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF we use a rat cardiac arrest model (VF induction, 6min no-flow, resuscitation) and administer NAC (150mg/kg IP at 5min post-ROSC), ferrostatin-1 (10mg/kg IP at 5min post-ROSC), or combination for 3 4-HNE+ cell density (cells/mm^2) in motor cortex; neuron count in caudo-putamen; neurodeficit score; combination expected to show >50% reduction in 4-HNE vs. mo— no observation —pending0.55
IF we stratify post-cardiac arrest patients by baseline plasma nitrotyrosine levels (high vs. low tertiles) and administer NAC (150mg/kg IV bolus then 50mg/kg/h for 24h) vs. placebo within 6 hours of Neurofilament light chain (NfL) concentration at 72h post-ROSC; expected 25% reduction in high-nitrotyrosine group— no observation —pending0.45
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF we use a rat cardiac arrest model (VF induction, 6min no-flow, resuscitation) and administer NAC (150mg/kg IP at 5min post-ROSC), ferrostatin-1 (10mg/kg IP at 5min post-ROSC), or combination for 3 days, THEN the combination will reduce cortical 4-HNE+ cells by >50% and preserve caudo-putamen neur
Predicted outcome: 4-HNE+ cell density (cells/mm^2) in motor cortex; neuron count in caudo-putamen; neurodeficit score; combination expected to show >50% reduction in 4-
Falsification: Combination produces <20% improvement over the better monotherapy on any primary endpoint, or ferrostatin-1 shows no additional benefit beyond NAC on lipid peroxidation markers, indicating the mechani
pendingconf 45%
IF we stratify post-cardiac arrest patients by baseline plasma nitrotyrosine levels (high vs. low tertiles) and administer NAC (150mg/kg IV bolus then 50mg/kg/h for 24h) vs. placebo within 6 hours of ROSC, THEN patients with high nitrotyrosine will show a 25% greater reduction in serum neurofilament
Predicted outcome: Neurofilament light chain (NfL) concentration at 72h post-ROSC; expected 25% reduction in high-nitrotyrosine group
Falsification: No significant difference in NfL between NAC and placebo in either tertile, or the low-nitrotyrosine group shows greater absolute reduction than the high-nitrotyrosine group, indicating NAC does not a
View on SciDEX ↗